IVERIC bio, Inc.
IVERIC bio, Inc. (ISEE): 6 pipeline candidates · ~30 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
30.3 months
D/E 0.29 · 0% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for IVERIC bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$467.6M
Quarterly Burn
$50.6M
Runway
30.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in IVERIC bio, Inc.'s pipeline?
IVERIC bio, Inc. (ISEE) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IVERIC bio, Inc.'s lead drug candidate?
IVERIC bio, Inc.'s most advanced tracked candidate is avacincaptad pegol (Phase 3) for Geographic Atrophy.
What is IVERIC bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IVERIC bio, Inc. has approximately 30.3 months of cash runway.
Who is the CEO of IVERIC bio, Inc.?
Akorn Inc is the chief executive officer of IVERIC bio, Inc. (ISEE).
Get the full picture on IVERIC bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.